# A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal

> **NCT03666715** · — · COMPLETED · sponsor: **Janssen-Cilag Farmaceutica Ltda.** · enrollment: 55 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Oral Antipsychotics (OAPs)
- **DRUG:** Paliperidone Palmitate 1-Month Formulation (PP1M)

## Key facts

- **NCT ID:** NCT03666715
- **Lead sponsor:** Janssen-Cilag Farmaceutica Ltda.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-07
- **Primary completion:** 2021-05-31
- **Final completion:** 2021-05-31
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03666715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03666715, "A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03666715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*